Conclusively, miRNA-seq of CD138+ plasma cells highlighted the significant downregulation of miR-221/222 expression in R-ISS III MM patients, while the analysis of our screening and two independent validation MM cohorts confirmed the significantly higher risk for short-term progression and worse survival outcome of the MM patients with miR-221/222 loss. The gene discussed is SDC1; the disease is Miyoshi myopathy.